Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

Watchlist Manager
Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Watchlist
Price: 21.63 USD 0.56% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Arrowhead Pharmaceuticals Inc?
Write Note

Intrinsic Value

ARWR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ARWR stock under the Base Case scenario is 28.34 USD. Compared to the current market price of 21.63 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ARWR Intrinsic Value
28.34 USD
Undervaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arrowhead Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ARWR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ARWR?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Arrowhead Pharmaceuticals Inc

Provide an overview of the primary business activities
of Arrowhead Pharmaceuticals Inc.

What unique competitive advantages
does Arrowhead Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Arrowhead Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of Arrowhead Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Arrowhead Pharmaceuticals Inc.

Provide P/S
for Arrowhead Pharmaceuticals Inc.

Provide P/E
for Arrowhead Pharmaceuticals Inc.

Provide P/OCF
for Arrowhead Pharmaceuticals Inc.

Provide P/FCFE
for Arrowhead Pharmaceuticals Inc.

Provide P/B
for Arrowhead Pharmaceuticals Inc.

Provide EV/S
for Arrowhead Pharmaceuticals Inc.

Provide EV/GP
for Arrowhead Pharmaceuticals Inc.

Provide EV/EBITDA
for Arrowhead Pharmaceuticals Inc.

Provide EV/EBIT
for Arrowhead Pharmaceuticals Inc.

Provide EV/OCF
for Arrowhead Pharmaceuticals Inc.

Provide EV/FCFF
for Arrowhead Pharmaceuticals Inc.

Provide EV/IC
for Arrowhead Pharmaceuticals Inc.

Show me price targets
for Arrowhead Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Arrowhead Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Arrowhead Pharmaceuticals Inc?

What are the Net Income projections
for Arrowhead Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Arrowhead Pharmaceuticals Inc?

What are the EPS projections
for Arrowhead Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Arrowhead Pharmaceuticals Inc?

What are the EBIT projections
for Arrowhead Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Arrowhead Pharmaceuticals Inc?

Compare the revenue forecasts
for Arrowhead Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Arrowhead Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Arrowhead Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Arrowhead Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Arrowhead Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Arrowhead Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Arrowhead Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Arrowhead Pharmaceuticals Inc.

Provide ROE
for Arrowhead Pharmaceuticals Inc.

Provide ROA
for Arrowhead Pharmaceuticals Inc.

Provide ROIC
for Arrowhead Pharmaceuticals Inc.

Provide ROCE
for Arrowhead Pharmaceuticals Inc.

Provide Gross Margin
for Arrowhead Pharmaceuticals Inc.

Provide Operating Margin
for Arrowhead Pharmaceuticals Inc.

Provide Net Margin
for Arrowhead Pharmaceuticals Inc.

Provide FCF Margin
for Arrowhead Pharmaceuticals Inc.

Show all solvency ratios
for Arrowhead Pharmaceuticals Inc.

Provide D/E Ratio
for Arrowhead Pharmaceuticals Inc.

Provide D/A Ratio
for Arrowhead Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Arrowhead Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Arrowhead Pharmaceuticals Inc.

Provide Quick Ratio
for Arrowhead Pharmaceuticals Inc.

Provide Current Ratio
for Arrowhead Pharmaceuticals Inc.

Provide Cash Ratio
for Arrowhead Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Arrowhead Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Arrowhead Pharmaceuticals Inc?

What is the current Free Cash Flow
of Arrowhead Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Arrowhead Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Arrowhead Pharmaceuticals Inc

Current Assets 450.1m
Cash & Short-Term Investments 436.7m
Other Current Assets 13.4m
Non-Current Assets 433.7m
PP&E 420.3m
Intangibles 9m
Other Non-Current Assets 4.5m
Current Liabilities 96.7m
Accounts Payable 26.6m
Accrued Liabilities 69.7m
Other Current Liabilities 417k
Non-Current Liabilities 456.5m
Other Non-Current Liabilities 456.5m
Efficiency

Earnings Waterfall
Arrowhead Pharmaceuticals Inc

Revenue
19.6m USD
Operating Expenses
-566.9m USD
Operating Income
-547.2m USD
Other Expenses
8.6m USD
Net Income
-538.6m USD

Free Cash Flow Analysis
Arrowhead Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Arrowhead reported a net loss of $170.8 million for Q3 2024, largely due to increased R&D expenses and decreased revenue. The company is transitioning into a commercial stage, focusing on launching its first product, plozasiran, aimed at familial chylomicronemia syndrome (FCS) by next year's end, supported by successful Phase III trials. A recent $500 million credit facility significantly bolstered Arrowhead's balance sheet, ensuring robust liquidity. Arrowhead is also advancing clinical trials in multiple therapeutic areas, including its pipeline of RNAi therapeutics, with further updates anticipated at upcoming webinars and conferences.

What is Earnings Call?
Fundamental Scores

ARWR Profitability Score
Profitability Due Diligence

Arrowhead Pharmaceuticals Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
9/100
Profitability
Score

Arrowhead Pharmaceuticals Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

ARWR Solvency Score
Solvency Due Diligence

Arrowhead Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
55/100
Solvency
Score

Arrowhead Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARWR Price Targets Summary
Arrowhead Pharmaceuticals Inc

Wall Street analysts forecast ARWR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARWR is 48.23 USD with a low forecast of 20.2 USD and a high forecast of 74.55 USD.

Lowest
Price Target
20.2 USD
7% Downside
Average
Price Target
48.23 USD
123% Upside
Highest
Price Target
74.55 USD
245% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ARWR?

Click here to dive deeper.

Dividends

Arrowhead Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ARWR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

ARWR News

Other Videos

Profile

Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.7B USD

Dividend Yield

0%

Description

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 329 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The firm's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

Contact

CALIFORNIA
Pasadena
177 E Colorado Blvd, Suite 700
+16266964702.0
arrowheadpharma.com

IPO

1993-12-14

Employees

329

Officers

CEO, President & Director
Dr. Christopher R. Anzalone Ph.D.
Chief Financial Officer
Mr. Kenneth A. Myszkowski
COO, General Counsel & Secretary
Mr. Patrick O'Brien J.D., PharmD
Chief of Discovery & Translational Medicine
Dr. James C. Hamilton M.D., MBA
Founder and Founder & Director of Insert Therapeutics Inc & Calando
Dr. Mark M. Davis Ph.D.
Head of Investor Relations & VP
Dr. Vincent Anzalone CFA
Show More
Director of Communications
Mr. Howard Lovy
Chief Medical Scientist
Dr. Bruce D. Given M.D.
Head of Toxicology & VP
Dr. Mark Seefeld
Chief Commercial Officer
Ms. Tracie Oliver
Show Less

See Also

Discover More
What is the Intrinsic Value of one ARWR stock?

The intrinsic value of one ARWR stock under the Base Case scenario is 28.34 USD.

Is ARWR stock undervalued or overvalued?

Compared to the current market price of 21.63 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 24%.

Back to Top